Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review

This narrative review found that current randomised-trial and meta-analytic evidence shows no clear increase in breast cancer incidence with the weight-loss drug tirzepatide (Mounjaro) or other GLP-1 receptor agonists. Rapid weight loss can make benign breast lesions easier to feel and can alter breast density on imaging, but available data do not suggest imaging accuracy is reduced. The authors recommend maintaining standard triple assessment and reassuring patients about breast cancer risk.

Narrative review. Population: women in breast screening and symptomatic clinics using tirzepatide or GLP-1 receptor agonists. Interventions: Tirzepatide (Mounjaro); GLP-1 receptor agonists.

Randomised-trial data and meta-analyses show no clear evidence of increased breast cancer incidence with tirzepatide or GLP-1 receptor agonists. In preclinical obesity-associated breast cancer models, tirzepatide-induced weight loss and metabolic improvement reduced mammary tumour progression. Clinical use of GLP-1 receptor agonists in women with breast cancer was associated with clinically meaningful weight loss without short-term safety signals. Weight loss decreases breast volume and subcutaneous fat, often making pre-existing benign lesions more palpable and altering mammographic density, but available data do not indicate reduced imaging accuracy.

This paper consolidates current evidence on tirzepatide and breast cancer risk, detection, and imaging, giving researchers a broad overview of the field. It does not establish a causal relationship or long-term safety profile for tirzepatide, as no prospective trials of breast cancer outcomes are reported.

Key findings

• Randomised-trial data and meta-analyses show no clear evidence of increased breast cancer incidence with tirzepatide or GLP-1 receptor agonists.
• Preclinical studies in obesity-associated breast cancer models show reduced mammary tumour progression after tirzepatide-induced weight loss.
• In women with breast cancer, GLP-1 receptor agonist use is associated with clinically meaningful weight loss without short-term safety signals.
• Weight loss decreases breast volume and subcutaneous fat and can make benign lesions more palpable, but available data do not indicate reduced imaging accuracy.
• Weight loss changes mammographic density and parenchymal patterns.

Limitations

• Authors note that high-quality prospective imaging and oncology studies are needed to define long-term effects.
• Clinical relevance of preclinical findings remains uncertain.
• Narrative review design, not systematic, so may not capture all relevant studies.
• Only short-term safety signals were available; long-term safety and outcomes are not yet established.

The record

• Journal: Cureus 18(6): e111445
• Published: 2026-06-01
• PMID: 42388957 — DOI: 10.7759/cureus.111445

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….